NHS to trial innovative cancer blood test

The NHS is trialling an innovative new blood test that may be able to detect more than 50 types of cancer. The Galleri blood test, developed by a company called GRAIL, will be piloted with 165,000 patients. Prior research on patients with signs of cancer has already found that the test, which checks for molecular […]

read more

Managing adverse events in kidney cancer patients on immunotherapy/TKI combination treatment

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center, Texas in the USA talks about managing adverse events to immunotherapy and targeted therapy combinations. There are more adverse events from any type of combination treatment compared to single treatments, especially immune adverse events. Nivolumab alone is very well tolerated and quite easy […]

read more

Cabozantinib plus atezolizumab for non-clear cell kidney cancer

In this video interview, Dr Monty Pal from the City of Hope Hospital in California talks about a subset of patients in the COSMIC-021 (cohort 10) with non-clear cell RCC, such as papillary renal cell carcinoma (RCC) and chromophobe RCC. Response rates exceeded 30%, which are very promising findings compared to TKIs alone. However, not […]

read more

Managing immune-related adverse events

In these video interviews, Dr Eric Jonasch from MD Anderson Cancer Center in Texas and Dr Monty Pal from the City of Hope Hospital in California talk about immune-related adverse events in people with advanced kidney cancer taking combination therapies and immunotherapy: Managing Adverse Events Among RCC Patients Receiving Combination Treatment With Targeted Therapy and […]

read more

Probiotic supplements and improves clinical benefit in kidney cancer

This prospective, randomised study in 20 people looked at the ability of probiotic supplements to modify the clinical benefit of targeted therapy (VEGF-TKIs cabozantinib or sunitinib) in metastatic renal cell carcinoma patients. The study showed that in people with metastatic RCC, the clinical benefit rate was similar in people taking probiotics compared to those who […]

read more

Lenvatinib plus everolimus for non clear cell kidney cancer

Treating non-clear cell renal cell carcinoma (RCC) is challenging because these diseases are rare, and so far there are no effective treatments for this group of patients. Non-clear cell RCC is currently treated in a similar way to clear cell RCC. In a phase 2 clinical trial, 31 patients with non-clear cell RCC were treated […]

read more
Showing 1 to 6 of 1006 results